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OBJECTIVES The purpose of this study was to investigate the role of hormone replacement therapy (HRT)
in postmenopausal women who smoke.
BACKGROUND Hormone replacement therapy appears to afford cardiovascular protection in postmenopausal
women; however, in high risk individuals, specifically smokers, this has not been adequately
studied. This question was addressed in a cross-sectional study of arterial structure, function
and plasma lipids in postmenopausal smokers and nonsmokers.
METHODS Vascular ultrasound was performed in two age-matched groups of postmenopausal women,
70 on HRT (35 smokers) and 70 control subjects not on HRT (35 smokers). Indexes of
arterial structure (carotid intima–media thickness [IMT]) and vascular function (systemic
arterial compliance [SAC]) and lipid profiles were measured.
RESULTS Participant characteristics were similar in the two groups. Smokers on HRT, compared with
smoking control subjects, had lower cholesterol (6.0 6 0.2 vs. 6.8 6 0.3 mmol/liter, p 5 0.03)
and more favorable mean values for IMT (0.64 6 0.02 vs. 0.74 6 0.03 mm, p 5 0.007) and
SAC (0.41 6 0.03 vs. 0.32 6 0.03 U/mm Hg, p 5 0.03). Nonsmokers on HRT compared
with nonsmoking control subjects had lower total cholesterol (5.7 6 0.2 vs. 6.5 6 0.2
mmol/liter, p 5 0.02) and low density lipoprotein cholesterol (3.4 6 0.2 vs. 4.4 6 0.3
mmol/liter, p 5 0.01). Mean IMT and SAC values in nonsmokers on HRT and control
subjects were not significantly different. Multiple regression demonstrated significant corre-
lation between HRT status and both IMT and SAC, in smokers and in those with increased
cholesterol. In nonsmokers and those with lower cholesterol, HRT status was not signifi-
cantly correlated with vascular parameters.
CONCLUSIONS In postmenopausal women who smoke there may be a beneficial effect of long-term estrogen
therapy on indexes of arterial structure and function as surrogate markers of cardiovascular
disease. Long-term controlled studies are needed to confirm these findings. (J Am Coll
Cardiol 1999;34:131–7) © 1999 by the American College of Cardiology
Vascular disease is the leading cause of death among
postmenopausal women in the western world. There have
been 75 original observational and epidemiologic studies
published on prevention of ischemic heart disease by hor-
mone replacement therapy (HRT). This evidence supports
a 40% to 50% reduction in the relative risk of cardiovascular
disease in postmenopausal women on HRT (1–3).
The proposed mechanisms of estrogen action on athero-
sclerotic vascular disease and on vascular structure and
function are diverse (4–6). Estrogen improves lipid profiles,
with higher high density lipoprotein (HDL) and lower total
and low density lipoprotein (LDL) cholesterol (7) and
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inhibits lipoprotein oxidation (8). In animal models estro-
gen reduces coronary intimal plaque development (9) and
inhibits proliferation of vascular smooth muscle cells (10).
Beneficial changes in carbohydrate metabolism, body fat
distribution (7), fibrinolysis and coagulation profiles (11,12)
have been noted. Endothelial function mediated by nitric
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oxide is also improved by estrogen (5). Impaired endothelial
function has been demonstrated in smokers, along with
altered lipid oxidation and increased atherosclerosis (8,13)
contributing to an increased risk of cardiovascular disease.
Potentially estrogen therapy may reduce cardiovascular risk
in postmenopausal smokers through these and other mech-
anisms.
The role of estrogen therapy in cardiovascular protection
in smokers is unclear. No specific observational or interven-
tional trials have focused on the role of HRT in smokers.
Several observational studies on cardiovascular protection
and HRT have performed subgroup analyses in smokers
with conflicting results; however, most have had inadequate
sample sizes to address the issue (1,2). The results of
long-term, prospective controlled trials are underway, with
the projected statistical power to confirm the cardiovascular
protective effect of HRT in postmenopausal women. To
date the only controlled interventional trial completed is the
Heart and Estrogen/Progestin Replacement Study (HERS)
(14), a secondary prevention study in older women with
established vascular disease treated with combined contin-
uous medroxyprogesterone acetate with conjugated equine
estrogen. This and other ongoing controlled trials do not
analyze specific high risk subgroups including smokers, with
specific intervention studies in smokers unlikely to be
feasible given the costs involved and numbers required.
As an alternative to large-scale intervention trials based
on clinical end points, noninvasive surrogate markers of
vascular disease have been developed as intermediate end
points. The early phase of atherosclerosis can be studied
using carotid artery intima–media thickness (IMT), a mea-
sure of vascular structure. In large population studies IMT
was significantly correlated with all the major cardiovascular
risk factors (15–17) and was shown to be a useful surrogate
marker of coronary arterial disease (17). Prospective studies
have shown that IMT increases with age (15), yet women
on HRT exhibit blunted age-related changes in IMT (18).
Systemic arterial compliance (SAC), a measure of central
conduit artery mechanical properties, reflects the ability of
the proximal vascular system to convert pulsatile ventricular
flow into smooth continuous peripheral blood flow. Sys-
temic arterial compliance is related to the elasticity of the
vessels and is influenced by age, hypertension, atheroscle-
rotic vascular disease, exercise training and lipid-lowering
and antihypertensive drugs (19–22). Hormone replacement
therapy has been demonstrated to significantly improve
arterial compliance in the short term (4).
In this study we have measured plasma lipids, IMT and
SAC in a large group of postmenopausal women on HRT
and an age-matched control group. We specifically sought
to determine whether HRT had protective vascular benefits
in smokers, with half of the population in each group being
smokers.
METHODS
Postmenopausal women were recruited by advertisement
from an urban population in Melbourne, Australia. Partic-
ipants were studied as a baseline assessment before enroll-
ment in an interventional study focusing on the use of
antioxidants in the prevention of cardiovascular disease.
One hundred and forty consecutive subjects were selected
based on HRT and smoking status with inclusion of
age-matched controls. All subjects were postmenopausal for
at least two years with the HRT group being current users
on therapy for at least one year. Seventy smokers (35 on
HRT and 35 control subjects) were compared with 70
nonsmokers (35 on HRT and 35 control subjects). Smokers
were defined as current smokers of a minimum of five
cigarettes per day with an average smoking history of 38.3
pack years. The primary estrogen used was conjugated
equine estrogen (Premarin) and the progestin was medroxy-
progesterone acetate (Provera). Forty-one were on estrogen
alone; 29 were on combined estrogen and progestin therapy.
Subjects were healthy as assessed from history questionnaire
(those with a history of osteoporosis were not excluded) and
no participants had uncontrolled hypertension. A question-
naire based on the National Heart Foundation of Australia
Risk Factor Prevalence study was completed by each par-
ticipant to assess cardiovascular risk factors (23). Vascular
parameters were ascertained in all participants; fasting total
LDL and HDL cholesterol and triglycerides were measured
in 100 participants. Height, weight and heart rate were
determined and multiple blood pressure readings obtained
in all participants.
The Human Research and Ethics Committee, Southern
Health Care Network, Melbourne approved the study
protocol. Informed consent was obtained from all subjects.
Participants were advised against consuming caffeine-
containing drinks for 8-h before ultrasound measurements,
which were performed in a quiet air-conditioned clinical
laboratory after subjects had been resting in the supine
position for at least 10 min. Serum samples for lipid profile
analyses were collected after an 8-h fast.
Vascular Parameters
Intima–media thickness. This parameter was derived from
noninvasive ultrasound of the common carotid arteries, using a
high resolution ultrasound machine (Diasonics DRF-400,
Milipitas, California) with 7.5-MHz mechanical sector trans-
ducer (7.5-SPC). The IMT was defined as the distance
Abbreviations and Acronyms
ANOVA 5 analysis of variance
HDL 5 high density lipoprotein
HRT 5 hormone replacement therapy
IMT 5 intima–media thickness
LDL 5 low density lipoprotein
SAC 5 systemic arterial compliance
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between the blood–intima and media–adventitia boundaries on
B-mode imaging (24). The far wall of the right common
carotid artery 1 cm proximal to the origin of the bulb was
selected, as it has been shown to be the most reproducible (25).
Three B-mode images were recorded from different angles,
then digitized and saved on computer via a customized
computer program using “A House of Windows” software (C.
Smith, Auckland, New Zealand) as previously described (26).
Brachial blood pressure recordings were recorded at 5-min
intervals throughout the imaging period using a Dinamap
device (Critikon, 1846 SX, Tampa, Florida). Image analysis
was performed using a standardized measurement protocol,
using 30 data points per subject, by the same sonographer (18).
Measurements were automatically transferred and saved in a
database (Quest for Windows, version 2.1, Gupta Corp.).
Total systemic arterial compliance. Assessment of SAC
was based on the classical two-element Windkessel model
and the “area method” calculation of Liu et al. (27).
Noninvasive determination of blood flow using Doppler
techniques and pressure waveforms obtained with applana-
tion tonometry were applied to determine SAC as previ-
ously described (18,22,27). Aortic volumetric blood flow
was measured from a handheld 3.5-MHz continuous wave
Doppler flow velocimeter (Multidoplex MD1, Huntleigh
Technology, Cardiff, U.K.) at the suprasternal notch. Si-
multaneous carotid driving pressure was ascertained by
applanation tonometry with a pressure transducer (Millar
Mikro-tip, Millar Instruments, Houston, Texas) over the
carotid artery, with pressures calibrated against Dinamap
brachial artery pressure measurements (Critikon 1846 SX).
The following formula was used to calculate compliance
over the total systemic arterial tree (22,27): SAC 5 Ad/
R(Ps 2 Pd), where Ad 5 area under the blood pressure
diastolic decay curve from end-systole to end-diastole; Ps 5
end-systolic blood pressure (carotid); Pd 5 end-diastolic
blood pressure (carotid); and R 5 total peripheral resistance
derived from blood pressure and aortic root blood flow
measurements.
A recent repeatability study was completed in 50 adult
participants who attended twice in one month with no
change in therapy or lifestyle. Bland-Altman plots showed
satisfactory repeatability for IMT and SAC, with a coeffi-
cient of variation of 2.8% and 9.2%, respectively (28).
Statistical Analysis
All parameters were normally distributed. The Student
unpaired t test was used to compare differences in mean
values for group characteristics, lipids, IMT and SAC
measurements overall and for smoking and nonsmoking
groups. An analysis of variance (ANOVA) was applied to
further assess the interaction between HRT and smoking
on IMT and SAC. Independent associations of estrogen
use were assessed by multiple linear regression with all
measures entered as continuous variables. Regression
models based on cardiovascular risk factors incorporating
age, body mass index, blood pressure variables and lipid
profiles were used to examine the independent relation-
ships between IMT, SAC, lipids and HRT status. With
SAC analyses blood pressure parameters were excluded in
the statistical model, as calculation of SAC is based on
blood pressure. All analyses were performed by using the
SPSS statistical package version 8. Data are given as
mean 6 SEM.
RESULTS
Baseline characteristics. Characteristics including age,
height, weight, body mass index and blood pressure param-
eters were similar in the HRT and control groups overall as
well as in smokers and nonsmokers (Table 1). Duration of
HRT was similar in the smokers compared with nonsmok-
ers (79 6 11 vs. 80 6 2 months, p 5 0.9).
Lipid profiles. Mean plasma total and LDL cholesterol
was significantly lower and HDL cholesterol was higher in
those on HRT compared with control subjects (Table 2). In
smokers, those on HRT had lower total cholesterol, but
there were no significant differences between smokers on
HRT and non-HRT control subjects for mean values of
LDL, HDL and triglycerides. In nonsmokers total and
Table 1. Characteristics of the Study Population: HRT Versus Control Subjects in the Overall Study Population and in Smokers and
in Nonsmokers
Characteristics








Age (yr) 60 6 1 60 6 1 0.8 60 6 1 60 6 1 0.9 60 6 1 60 6 1 0.8
Height (m) 1.62 6 0.01 1.61 6 0.01 0.3 1.62 6 0.01 1.62 6 0.01 0.9 1.62 6 0.01 1.60 6 0.01 0.2
Weight (kg) 67 6 1 68 6 2 0.4 66 6 2 68 6 2 0.4 67 6 2 68 6 2 0.7
BMI (kg/m2) 25 6 0.4 27 6 0.6 0.1 25 6 0.6 27 6 1 0.2 26 6 0.6 27 6 0.8 0.3
Systolic BP (mm Hg) 134 6 2 134 6 2 1 134 6 3 135 6 3 0.9 134 6 4 134 6 4 0.9
Diastolic BP (mm Hg) 74 6 1 74 6 1 0.7 74 6 1 74 6 2 0.9 74 6 2 75 6 1 0.6
Mean BP (mm Hg) 94 6 1 94 6 1 0.9 94 6 2 94 6 2 0.9 94 6 2 92 6 2 0.7
Results are presented as mean 6 SEM.
BMI 5 body mass index; BP 5 blood pressure; HRT 5 hormone replacement therapy.
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LDL cholesterol were lower in those on HRT compared
with control subjects.
Intima–media thickness. Group and subgroup compari-
sons for IMT are shown in Table 3 and Figure 1. Mean
IMT was similar in smokers and nonsmokers. For all
subjects, those on HRT had an IMT lower than that of
control subjects. This was seen particularly in the smokers
on HRT, where mean IMT was 13% lower than in control
subjects not on HRT. The difference in the mean values for
nonsmokers was not significant. A subgroup analysis of
estrogen versus combined therapy did not reveal any signif-
icant differences between these two groups (0.67 6 0.1 vs.
0.65 6 0.1 mm, p 5 NS).
An ANOVA adjusted for cardiac risk factors demon-
strated significant interaction between HRT and IMT (p 5
0.006); however, smoking status was not significantly cor-
related with IMT, with the combined interaction term
failing to reach significance.
In a stepwise multiple regression analysis, for all subjects,
IMT was significantly related to pulse pressure (p 5 0.001),
HRT status (p 5 0.02) and triglyceride level (p 5 0.04). In
smokers, IMT correlated with systolic blood pressure (p 5
0.001), HRT status (p 5 0.02) and triglyceride level (p 5
0.02); in nonsmokers IMT was correlated only with pulse
pressure (p 5 0.004).
In those subjects with high total cholesterol
(.6.2 mmol/liter, the median for the group), IMT was
significantly correlated with systolic blood pressure (p 5 0.001)
and HRT status (p 5 0.01), whereas for those with cholesterol
levels #6.2 mmol/liter, IMT was correlated only with systolic
(p 5 0.0001) and diastolic blood pressure (p 5 0.01).
Systemic arterial compliance. Group and subgroup com-
parisons for SAC are shown in Table 3 and Figure 1. Mean
SAC was lower in smokers compared with nonsmokers
(p 5 0.01). For all subjects and for smokers, those on HRT
had a more favorable (higher) SAC than control subjects
not on HRT. For nonsmokers mean SAC values were
similar in the HRT and control subgroups. A subgroup
analysis of estrogen versus combined therapy did not reveal
any significant differences between these two groups
(0.45 6 0.2 vs. 0.40 6 0.2, p 5 NS).
An ANOVA adjusted for cardiac risk factors demon-
strated significant interaction between HRT and SAC
(p 5 0.04) and between smoking status and SAC (p 5
0.05), and a significant smoking–HRT interaction term
(p 5 0.006).
Stepwise multiple regression analysis showed that for all
subjects SAC was correlated with age (p 5 0.008), HRT
status (p 5 0.02) and smoking (p 5 0.05). In smokers,
HRT status was the only significant correlate of SAC (p 5
0.0001). In nonsmokers HRT status was not significantly
correlated with SAC. In those participants with cholesterol
.6.2 mmol/liter HRT use was significantly related to SAC
Table 2. Lipid Profiles: HRT Versus Control Subjects in All Subjects and in Smokers and in Nonsmokers
Characteristics
All Subjects Smokers Nonsmokers
HRT Controls p Value HRT Controls p Value HRT Controls p Value
Total cholesterol
(mmol/liter)
5.8 6 0.1 6.6 6 0.1 0.001 6.0 6 0.2 6.8 6 0.3 0.03 5.7 6 0.2 6.5 6 0.3 0.02
LDL cholesterol
(mmol/liter)
3.5 6 0.1 4.2 6 0.2 0.007 3.6 6 0.2 4.0 6 0.2 0.2 3.4 6 0.2 4.4 6 0.3 0.01
HDL cholesterol
(mmol/liter)
1.8 6 0.1 1.6 6 0.1 0.02 1.7 6 0.1 1.6 6 0.1 0.4 1.8 6 0.1 1.5 6 0.1 0.08
Triglyceride
(mmol/liter)
1.4 6 0.1 1.6 6 0.2 0.4 1.7 6 0.2 1.8 6 0.3 0.7 1.2 6 0.1 1.4 6 0.2 0.3
Results are presented as mean 6 SEM.
HDL 5 high density lipoprotein; HRT 5 hormone replacement therapy; LDL 5 low density lipoprotein.
Table 3. Comparison of Group Values for IMT and SAC
Groups Subgroups SAC (U/mm Hg) p Value IMT (mm) p Value
All subjects Smokers 0.36 6 0.02 0.70 6 0.02
Nonsmokers 0.44 6 0.02 0.01 0.69 6 0.02 0.6
All subjects HRT 0.43 6 0.02 0.66 6 0.01
Controls 0.37 6 0.02 0.06 0.73 6 0.02 0.006
Smokers HRT 0.41 6 0.03 0.64 6 0.02
Controls 0.32 6 0.03 0.03 0.74 6 0.03 0.007
Nonsmokers HRT 0.45 6 0.03 0.68 6 0.02
Controls 0.43 6 0.03 0.6 0.72 6 0.03 0.3
HRT 5 hormone replacement therapy; IMT 5 intima–media thickness; SAC 5 systemic arterial compliance.
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(p 5 0.004), whereas for those with cholesterol levels
#6.2 mmol/liter there was no relationship between HRT
use and SAC.
DISCUSSION
Smoking and vascular disease. Postmenopausal women
who are smokers have double the risk of vascular disease
compared with nonsmokers, equivalent to those with dia-
betes or documented prior myocardial infarction (2,29).
Mechanisms contributing to the increased risk in smokers
include accelerated atherosclerosis, coronary spasm, throm-
bosis risk and endothelial dysfunction (13). Smoking also
promotes an acceleration of age-related increases in carotid
artery IMT (18) that may relate to increased lipid peroxi-
dation (8). Although a major public health goal is to achieve
nonsmoking status in the whole community, there is a need
for therapies that have cardiovascular protective effects in
smokers, including postmenopausal women who smoke.
Although estrogen therapy appears to be cardioprotective
in postmenopausal women, there is controversy over
whether women who smoke derive equivalent benefits from
HRT compared with nonsmokers. Published observational
and case–control data are conflicting. Data from the Fra-
mingham study suggest that smokers on estrogen have
increased cardiovascular mortality (29), whereas all other
studies have found no deleterious effects in smokers
(1,3,30,31). Many found cardiovascular protection with
HRT occurred irrespective of smoking status (1,30). Al-
though it has been suggested that smokers may have
reduced benefits compared with nonsmokers (3), it has been
noted that estrogen-treated smoking women have a signif-
icant reduction in the incidence of stroke, a finding not
observed in nonsmokers (31). Disappointingly the majority
of observational studies and the only published controlled
interventional trial have not specifically addressed the
HRT–smoking interaction, largely due to inadequate sam-
ple size (1,2,14).
Data interpretation. The results of the present study
suggest that postmenopausal smoking women on HRT have
significantly more favorable indexes of early atherosclerosis
(IMT) and arterial compliance (SAC) compared with age-
matched control subjects not on HRT. The apparent
beneficial effects of HRT in smokers persisted after correc-
tion for other vascular risk factors including blood pressure
and plasma lipids. In contrast, nonsmokers on HRT had
mean values for IMT and SAC that were similar to those of
nonsmoking control subjects. This suggests that those at
highest risk may derive greatest benefit from HRT. In
keeping with this hypothesis, in those participants with high
cholesterol levels (.6.2 mmol/liter), the median value for
the whole group, HRT use was significantly related to IMT
and SAC, whereas this was not the case for those with lower
cholesterol levels. A larger sample size may be necessary to
demonstrate apparent vascular benefits of HRT use in
postmenopausal women at lower levels of cardiovascular risk
(18,32). Likewise, the inability to demonstrate a relation-
ship between smoking and IMT in the present study is
likely to be a consequence of the relatively small sample size,
given that this has been well defined in large-population
studies (33).
In interpreting these results consideration must be given
to the potential for bias inherent in all observational studies,
specifically, the influence of a “healthy user bias,” whereby
women choosing to take HRT may vary from those not on
HRT, including better general health and level of education
(34). The recently published results of the HERS study are
also relevant to interpretation of these findings. This con-
trolled, well designed study focused on the secondary
prevention of vascular events with combined continuous
HRT use in women with established vascular disease (14).
No benefits of HRT were seen for a variety of clinical end
points including myocardial infarction and cardiac death.
There are some caveats to interpreting the HERS study.
First, it was a secondary prevention study in women with
coronary heart disease and the results cannot be extended to
the use of HRT in primary prevention. Second, combined
continuous medroxyprogesterone acetate and conjugated
equine estrogen was used, a combination recently demon-
strated in the cynamologous monkey model to be ineffective
in preventing atherosclerosis (35). Thus, there is the poten-
tial for differential effects of progestin subtypes and regi-
mens on the vascular system. In the present study we were
unable to demonstrate any differences between the estrogen
and estrogen plus progestin treatment groups. Medroxypro-
gesterone acetate was the predominant progestin used in the
Figure 1. Mean (6SEM) values for intima–media thickness
(IMT, upper panel) and systemic arterial compliance (SAC, lower
panel) in smokers and nonsmokers comparing those on long-term
hormone replacement therapy (HRT, solid bars) vs. control
subjects not on HRT (open bars). ppp 5 0.007, pp 5 0.03.
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combined HRT group. These results were consistent with
our previous findings in a larger cross-sectional study (18).
Still, the possibility exists that concomitant use of progestin
may tend to counteract the beneficial vascular effects of
estrogen in postmenopausal women. Prospective controlled
trials are required to address this question. Finally, in the
HERS study the mechanisms of HRT action may have
been obscured by the extensive therapies already in use in
these women, potentially negating any beneficial mecha-
nisms of estrogen action (14).
Mechanisms of estrogen action in smokers. In light of
the positive findings presented here, it is interesting to
consider the potential mechanisms of estrogen action on the
blood vessel wall. Three studies have suggested that HRT
affects carotid artery IMT. Manolio et al. (30) reported that
estrogen use was associated with reduced IMT after adjust-
ment for other risk factors. In a recent study, our group
reported that the age-related increase in IMT and fall in
SAC were attenuated in postmenopausal women on HRT
(18). Also, in a therapeutic trial of lipid-lowering therapy,
Espeland et al. (36) found that women on HRT had a
reduced rate of progression of carotid artery IMT. Hormone
replacement therapy is likely to exert some of its effects via
improved plasma lipids. However, the rapidity with which
functional changes can occur (4,5) and the observation from
this study that beneficial effects of HRT on IMT and SAC
persist after correction for lipid status clearly point toward
other mechanisms of action on arteries. Indirect effects via
modulation of vascular smooth muscle cells and of the
atherosclerotic process (9,10) as well as direct effects on
arterial tone and reactivity (37) have been demonstrated.
Higher SAC values have been noted in postmenopausal
women on HRT, with cessation of therapy leading to a
rapid fall in SAC values over four weeks (4). Estrogen
therapy can cause acute changes in flow-mediated vasodila-
tion of the brachial artery (5) and influence coronary
vasodilation (9), effects that are thought to be mediated by
the nitric oxide pathway. Just how estrogen affects endothe-
lial function and arterial compliance, and whether or not
these are necessary precursors of the atherosclerotic process,
have yet to be determined.
There are several important considerations regarding
HRT use in smokers. The first concerns potential harmful
effects. An early analysis of data from the Framingham
study raised concerns that estrogen may increase vascular
disease in all postmenopausal women, especially smokers
(29); this report was based on small numbers and subjective
end points (chest pain), and has not been confirmed in any
other studies. The relative risk of venous thromboembolism
in HRT compared with placebo is around 3:1 (14). How-
ever, these events are infrequent, with the baseline incidence
in postmenopausal women noted at 1 in 10,000 women per
year. Unlike high dose oral contraceptive pills, no excess risk
has been observed in smokers on HRT (38). Studies on
coagulation factors and fibrinolysis have either failed to
show an impact with HRT (12), or have demonstrated
increased fibrinolytic activity, a possible beneficial mecha-
nism of estrogen action (11). Also, estrogen metabolism is
altered in smokers, with dosage requirements, routes of
administration and the degree of benefit gained from HRT
still uncertain (39,40). In smokers, menopause occurs one to
two years earlier (41). Endogenous estrogen levels are lower
in smokers (41) with an associated reduction in the inci-
dence of estrogen-associated malignancies (41). In smokers,
oral estrogen therapy resulted in lower serum estradiol levels
and reduced (but still significant) improvement in both lipid
profiles and bone mineral content when compared with
those in nonsmokers (39,42). Consistent with this was the
observation in the present study that the apparent beneficial
effects of estrogen therapy were more evident in smokers
than nonsmokers. Interestingly, smokers appear to gain
equivalent benefit to nonsmokers if therapy is administered
transdermally (39,42).
Conclusions. Existing observational studies in women and
animal data strongly support a cardiovascular protective role
of HRT. The use of HRT in postmenopausal women who
smoke has been limited by lack of evidence and concerns
over risks of therapy. In this study, among chronic smokers
the use of HRT was associated with a lower mean carotid
wall thickness (IMT) and a higher central arterial compli-
ance (SAC), compared with those in smokers not on HRT.
These effects persisted after adjustment for other major risk
factors and suggest a particular benefit of HRT in smokers.
These results need to be interpreted with caution, given the
cross-sectional nature of the study and the relatively small
sample size.
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